General discussion, page-6191

Just one small thing - CPH has not acquired Halucenex yet.

As things stand, Halucenex doesn't compare favourably to IHL's psychedelics wing, and I'm trying to stay polite. They have no concretely announced trials, from what I can tell, and their lead physician, Niall J. Buckley, is a family doctor with pretty underwhelming patient ratings (LOL)...

https://www.ratemds.com/doctor-ratings/15682/Dr-Niall-Buckley-Windsor-NS.html/

I have found zero traces of him publishing or lecturing about anything remotely related to psilocybin. Erm...

On the other hand, our Dr Paul Liknaitzky has excellent credentials.
This is his field of expertise. For comparison, a straight cut and paste from his Linkedin bio:

"Head of the Clinical Psychedelic Research Lab within the Turner Institute and the Dept of Psychiatry, Monash. He is a Chief Principal Investigator and Research Fellow at Monash University, and has Adjunct or Honorary appointments at St Vincent’s Hospital, Macquarie University, Deakin University, and the University of Melbourne. He earned an Honours in Neuroscience and a PhD in Psychology from the University of Melbourne. His work examines mechanisms of mental illness and treatment development primarily within mood disorder and addiction research. Dr Liknaitzky is Principal Investigator across a number of Australia’s first clinical psychedelic trials. He has been invited to deliver numerous academic, professional, and public talks on psychedelic-assisted psychotherapy research, and has been interviewed on the topic for print media (eg, Griffiths Review, Guardian, Age, Sydney Morning Herald), radio (eg, ABC, 3CR), and podcasts (eg, Blindboy Podcast, The You Project). He is currently establishing a rigorous program of research in psychedelic medicine at Monash University that seeks to evaluate therapeutic effects, innovate on treatment design, mitigate known risks, explore potential drawbacks, and understand therapeutic mechanisms."

People should draw their own conclusions... I've drawn mine.